Search company, investor...

GenomeKey

genomekey.com

Stage

Grant | Alive

Total Raised

$3.26M

Last Raised

$3M | 2 yrs ago

About GenomeKey

GenomeKey diagnoses bacterial presence, species and antimicrobial resistance in the time span of an hour.

Headquarters Location

3 Bullock Way Newent

Gloucestershire, England, GL18 1UF,

United Kingdom

Missing: GenomeKey's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: GenomeKey's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing GenomeKey

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GenomeKey is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

8,565 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,901 items

Latest GenomeKey News

Carb-X awards up to $3m to GenomeKey for rapid sepsis diagnostic

Apr 28, 2021

Carb-X awards up to $3m to GenomeKey for rapid sepsis diagnostic 28 April 2021 CARB-X is awarding GenomeKey in Bristol up to $3 million in non-dilutive funding to develop a rapid diagnostic for sepsis. GenomeKey is eligible for up to $6.5 million in additional awards if the project achieves certain milestones, subject to available funds. × The new diagnostic would reduce the time it takes to determine what bacteria are causing an infection and which antibiotics would be most effective in treating a patient suffering from sepsis. The diagnostic would deliver precise test results in four hours rather than the several days it can currently take. Sepsis is a leading cause of hospital deaths in many countries. Globally, an estimated  11 million people die each year from sepsis . Recent studies report that sepsis kills at least 46,000 people per year in the UK with potential direct costs to the NHS at more than £1.8 billion per year. In the US, the toll is similar. An estimated 1.7 million American adults develop sepsis each year and nearly 270,000 die as a result, according to the US Centers for Disease Control and Prevention (CDC). This represents an estimated health care cost in the US of $62 billion annually. Erin Duffy, R&D chief of CARB-X, said: “Prompt diagnosis and treatment provide the best chance for reducing death rates and improving recovery from sepsis. GenomeKey’s innovative technology aims to accelerate diagnosis and deliver vital antibacterial susceptibility information that could take the guesswork out of treatment decisions in the first critical hours of illness.” Studies show that the risk of dying from sepsis increases by as much as 8% for every hour that treatment is delayed. Currently, it can take between 24 and 72 hours for laboratories to produce results. Dr Michael Roberts, GenomeKey CEO, said: “The technology GenomeKey is building will enable clinicians to diagnose and treat sepsis faster, and reduce unnecessary antibiotic consumption. Sepsis can kill within hours, and yet the gold standard test for this disease currently takes days. At GenomeKey, we are changing this by combining advances in DNA sequencing with our unique genomic technology and machine learning to deliver a next-generation diagnostic that will provide clinical answers in only hours and enable clinicians to confidently put their patients on targeted antibiotics sooner.”  GenomeKey’s diagnostic project aims to accurately determine the presence of bacteria from a blood sample, identify the bacterial species and determine its antibacterial susceptibility, all within a matter of hours. The technology combines innovative methods to separate bacterial DNA from human DNA in whole blood, next generation DNA sequencing and machine learning to interpret the antimicrobial susceptibility of the bacterial DNA. In normal circumstances, immune defences are capable of fighting off invading bacteria and viruses, but in sepsis, the invading pathogens overcome these defences, leading to rapid deterioration of the patient’s condition, and potentially to organ failure and death. Administration of the appropriate treatment early on, for example an antibiotic known to be effective against the bacteria, is vital. Some people are at higher risk of contracting infection and developing sepsis. These include the very young, the very old, those with chronic illnesses, and those with a weakened or impaired immune system.

GenomeKey Frequently Asked Questions (FAQ)

  • Where is GenomeKey's headquarters?

    GenomeKey's headquarters is located at 3 Bullock Way, Gloucestershire.

  • What is GenomeKey's latest funding round?

    GenomeKey's latest funding round is Grant.

  • How much did GenomeKey raise?

    GenomeKey raised a total of $3.26M.

  • Who are the investors of GenomeKey?

    Investors of GenomeKey include CARB-X and Bristol Private Equity Club.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.